Novo Nordisk and Ypsomed Selfcare Solutions

Novo Nordisk, a pharmaceutical golf-club founded in Denmark in 1923, has been a pioneer of innovative insulin preservation methods for the treatment of diabetes with brand name Levomir® (an barb pen that uses a pre-filled, replaceable insulin cartridge) and AERx® (an insulin inhalant). While Novo Nordisk continues to be the world leader in diabetes treatment, the caller-up has expanded into early(a) areas of look into and increase including human branch hormone and astringent products in their biopharmaceuticals. Biopharmaceuticals is the method of developing products by biological exercise earlier than chemical process oftentimes utilizing recombinant desoxyribonucleic acid, or DNA that is a combination of two or more organisms (Exploratorium, 2006). Ypsomed Selfcare Solutions, a smart set based in Burgdorf, Switzerland, was naturalised in 2003 as a result of the split of the Burgdorf-based Disetronic Groups and is as well as involved in the medical exam appliances and equipment industry. Ypsomed is involved in the development and manufacture of custom-make injection pens and compatible pen needles for the formation of self-injection solutions by patients (Ypsomed Selfcare Solutions, 2003-2006). The ships troupes products can swim be used for a variety of applications and therapies such as insulin therapy, growth hormone therapy, and osteoporosis and air glucose monitoring. Ypsomed currently distributes its products primarily in Europe, but expect their merchandise to grow worldwide collectible to the dramatic increase in diabetes cases.

PriceWaterhouseCoopers is the auditor of records for these two companies (Ypsomed annual Report, 2005 and Novo Nordisk annual Report, 2005). Novo Nordisk Financial Data-2005 Annual Report Novo Nordisk was the first Scandinavian company to be quoted on the refreshful York Stock Exchange, and is now an outside(a) company with representation in 69 countries (Wikipedia, 2005). The 2005 annual root states the company had a turnover of DKK 33.8 trillion, or approximately 4.5 billion EUR (X-rates, 2006). primitive sales for diabetes products... If you want to digest a unspoiled essay, holy order it on our website: Ordercustompaper.com

If you want to get a full essay, visit our page: write my paper